Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             40 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab Malmberg, Ruben

23 12 p. e552-e561
artikel
2 Aotearoa provides concrete examples for how to address inequities in health Jenei, Kristina

23 12 p. e524
artikel
3 2022 ASTRO annual meeting Gourd, Katherine

23 12 p. 1490-1491
artikel
4 Breast surgery after neoadjuvant chemotherapy: time for a change? Spanheimer, Philip M

23 12 p. 1477-1479
artikel
5 Climate-driven Atlantic hurricanes create complex challenges for cancer care Espinel, Zelde

23 12 p. 1497-1498
artikel
6 COP27 Climate Change Conference: urgent action needed for Africa and the world Atwoli, Lukoye

23 12 p. 1486-1488
artikel
7 Correction to Lancet Oncol 2022; 23: 1490–91
23 12 p. e531
artikel
8 Correction to Lancet Oncol 2022; 23: e480
23 12 p. e531
artikel
9 Dexamethasone for cancer-related dyspnoea Nishimura, Rumi

23 12 p. e525
artikel
10 Dexamethasone for cancer-related dyspnoea – Authors' reply Hui, David

23 12 p. e526
artikel
11 Diffuse peritoneal myofibroblastoma mimicking tuberculous peritonitis Yang, Yuhua

23 12 p. e562
artikel
12 Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial Kuerer, Henry M

23 12 p. 1517-1524
artikel
13 Essential anticancer medicines for children: defining what matters most for Europe Denburg, Avram

23 12 p. 1479-1480
artikel
14 Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE Otth, Maria

23 12 p. 1537-1546
artikel
15 Five fractions of SBRT for prostate cancer Achard, Vérane

23 12 p. e530
artikel
16 Fluorouracil and dose-dense adjuvant chemotherapy in breast cancer: lessons learned from the 20-year-old GIM2 trial Morganti, Stefania

23 12 p. 1482-1484
artikel
17 Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial Del Mastro, Lucia

23 12 p. 1571-1582
artikel
18 Gryt: amplifying more patient voices for better outcomes Craig, David

23 12 p. 1494
artikel
19 High hopes for a healthier Brazil with Lula's third mandate Triunfol, Marcia

23 12 p. e533
artikel
20 Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial Guadagnolo, B Ashleigh

23 12 p. 1547-1557
artikel
21 International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic Lee, Victor Ho-Fun

23 12 p. e544-e551
artikel
22 Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial Bénard, François

23 12 p. 1499-1507
artikel
23 Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study Botta, Laura

23 12 p. 1525-1536
artikel
24 Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy Martin, Jarad M

23 12 p. e534-e543
artikel
25 New survey and initiatives to support patients living with cancer Das, Manjulika

23 12 p. 1489
artikel
26 25 organisations added to tobacco industry allies database Burki, Talha Khan

23 12 p. 1493
artikel
27 Pembrolizumab as adjuvant therapy in non-small-cell lung cancer Uprety, Dipesh

23 12 p. e527
artikel
28 Pembrolizumab as adjuvant therapy in non-small-cell lung cancer Sorscher, Steven

23 12 p. e529
artikel
29 Pembrolizumab as adjuvant therapy in non-small-cell lung cancer Ganguly, Shuvadeep

23 12 p. e528
artikel
30 Preoperative hypofractionated radiotherapy for soft tissue sarcoma Roeder, Falk

23 12 p. 1481-1482
artikel
31 QT prolongation with anticancer drugs: a multimodal issue Raschi, Emanuel

23 12 p. e522
artikel
32 QT prolongation with anticancer drugs: a multimodal issue – Authors' reply Giraud, Eline L

23 12 p. e523
artikel
33 SABR for primary renal cell carcinoma: single-fraction or multiple-fraction? Mizowaki, Takashi

23 12 p. 1476-1477
artikel
34 Stakeholders welcome proposal on the European Health Data Space Das, Manjulika

23 12 p. 1492
artikel
35 Still waiting for a UK cancer plan that truly delivers The Lancet Oncology,

23 12 p. 1475
artikel
36 Telling the personal stories behind cancer at the Edinburgh Festival Fringe Ranscombe, Peter

23 12 p. 1495-1496
artikel
37 The Advisory Board on Cancer, Infertility and Pregnancy: a virtual on-demand multidisciplinary tumour board Amant, Frédéric

23 12 p. 1484-1486
artikel
38 US cancer drug prices do not reflect benefits to patients Furlow, Bryant

23 12 p. e532
artikel
39 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney) Siva, Shankar

23 12 p. 1508-1516
artikel
40 Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study Meric-Bernstam, Funda

23 12 p. 1558-1570
artikel
                             40 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland